Abstract
Tumor Treating Fields (TTFields) therapy specifically disrupts cellular processes necessary for cancer cell viability and tumor progression through the delivery of electric fields from a portable medical device. Patients with solid tumors such as glioblastoma experience significantly improved overall survival when receiving TTFields therapy concomitant with other standard-of-care therapies. TTFields therapy is also well tolerated and allows patients to maintain their quality of life. It is currently approved for the treatment of newly diagnosed and recurrent glioblastoma, pleural mesothelioma, and metastatic non–small cell lung cancer. Advanced practice providers (APPs), such as nurse practitioners, physician assistants, pharmacists, and other advanced oncology professionals, play key roles in the multidisciplinary team when implementing TTFields therapy. Advanced practice providers with prescribing authority can prescribe TTFields therapy after completing a one-time certification training. During the treatment decision-making process, APPs are poised to have in-depth conversations with patients and caregivers about TTFields therapy to help them grasp key concepts regarding efficacy and safety, how to properly use and integrate the device into their daily lives, cost of therapy, and how to get help using the various patient assistance programs. In addition, APPs play important roles in supporting optimal patient adherence and managing adverse events to ensure improved survival outcomes.
References
American Society of Clinical Oncology. (2023). Chemotherapy side effects. https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy/chemotherapy-side-effects.html
Anadkat, M. J., Lacouture, M., Friedman, A., Horne, Z. D., Jung, J., Kaffenberger, B.,...Grosso, F. (2023). Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region. Frontiers in Oncology, 12, 975473. https://doi.org/10.3389/fonc.2022.975473
Ballo, M. T., Conlon, P., Lavy-Shahaf, G., Kinzel, A., Vymazal, J., & Rulseh, A. M. (2023). Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: A systematic review and meta-analysis. Journal of Neuro-Oncology, 164(1), 1–9. https://doi.org/10.1007/s11060-023-04348-w
Barrington, D. A., Riedinger, C., Haight, P. J., Tubbs, C., & Cohn, D. E. (2022). Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis. Gynecologic Oncology, 165(3), 500–505. https://doi.org/10.1016/j.ygyno.2022.03.031
Batzianouli, E. T., Adams, R., Johnson, H., & Abdullah, H. (2023). Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users. Annals of Oncology, 34, S403. https://doi.org/10.1016/j.annonc.2023.09.1725
Bokstein, F., Blumenthal, D., Limon, D., Harosh, C. B., Ram, Z., & Grossman, R. (2020). Concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: A prospective safety and feasibility study. Frontiers in Oncology, 10, 411. https://doi.org/10.3389/fonc.2020.00411
Ceresoli, G. L., Aerts, J. G., Dziadziuszko, R., Ramlau, R., Cedres, S., van Meerbeeck, J. P.,...Grosso, F. (2019). Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): A multicentre, single-arm phase 2 trial. Lancet Oncology, 20(12), 1702–1709. https://doi.org/10.1016/S1470-2045(19)30532-7
Chen, J., Tong, X., Han, M., Zhao, S., Ji, L., Qin, Y.,...Liu, A. (2021). Cost-effectiveness of short-course radiation plus temozolomide for the treatment of newly diagnosed glioblastoma among elderly patients in China and the United States. Frontiers in Pharmacology, 12, 743979. https://doi.org/10.3389/fphar.2021.743979
Cherla, A., Renwick, M., Jha, A., & Mossialos, E. (2020). Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England. EClinicalMedicine, 29–30, 100625. https://doi.org/10.1016/j.eclinm.2020.100625
Frongillo, P., Gwyn, G., Wagenknech, C., Thomas, A., & Adams, N. (2022). Factors guiding the initiation of Tumor Treating Fields (TTFields; 200 kHz) therapy for glioblastoma: Self-reported patient and oncologist perspectives. S177.
Giladi, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Munster, M., Blat, R.,...Palti, Y. (2015). Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Scientific Reports, 5, 18046. https://doi.org/10.1038/srep18046
Guzauskas, G. F., Pollom, E. L., Stieber, V. W., Wang, B. C. M., & Garrison, L. P., Jr. (2019). Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: A cost-effectiveness study. Journal of Medical Economics, 22(10), 1006–1013. https://doi.org/10.1080/13696998.2019.1614933
Jackson, C. M., Choi, J., & Lim, M. (2019). Mechanisms of immunotherapy resistance: Lessons from glioblastoma. Nature Immunology, 20(9), 1100–1109. https://doi.org/10.1038/s41590-019-0433-y
Karanam, N. K., Srinivasan, K., Ding, L., Sishc, B., Saha, D., & Story, M. D. (2017). Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell Death & Disease, 8(3), e2711. https://doi.org/10.1038/cddis.2017.136
Kesari, S., Ram, Z., & EF-14 Trial Investigators. (2017). Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: A post hoc analysis of the EF-14 trial. CNS Oncology, 6(3), 185–193. https://doi.org/10.2217/cns-2016-0049
Kilias, M., & Pellet, C. (2017). Role of nurses for the implementation of ttfields in daily clinical routine in glioblastoma treatment. Neuro-Oncology, 19, vi209. https://doi.org/10.1093/neuonc/nox168
Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y.,...Palti, Y. (2004). Disruption of cancer cell replication by alternating electric fields. Cancer Research, 64(9), 3288–3295. https://doi.org/10.1158/0008-5472.can-04-0083
Lacouture, M. E., Anadkat, M. J., Ballo, M. T., Iwamoto, F., Jeyapalan, S. A., La Rocca, R. V.,...Glas, M. (2020). Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma. Frontiers in Oncology, 10, 1045. https://doi.org/10.3389/fonc.2020.01045
Lang, S. T., Gan, L. S., McLennan, C., Monchi, O., & Kelly, J. J. P. (2020). Impact of peritumoral edema during tumor treatment field therapy: A computational modelling study. IEEE Transactions on Biomedical Engineering, 67(12), 3327–3338. https://doi.org/10.1109/tbme.2020.2983653
Leal, T., Kotecha, R., Ramlau, R., Zhang, L., Milanowski, J., Cobo, M.,...Luna Study Investigators. (2023). Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): A randomised, open-label, pivotal phase 3 study. Lancet Oncology, 24(9), 1002–1017. https://doi.org/10.1016/S1470-2045(23)00344-3
Lok, E., Clark, M., Liang, O., Malik, T., Koo, S., & Wong, E. T. (2023). Modulation of tumor-treating fields by cerebral edema from brain tumors. Advances in Radiation Oncology, 8(1), 101046. https://doi.org/10.1016/j.adro.2022.101046
Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L.,...Butowski, N. (2014). Clinical practice experience with NovoTTF-100A system for glioblastoma: The Patient Registry Dataset (PRiDe). Seminars in Oncology, 41(Suppl 6), S4–S13. https://doi.org/10.1053/j.seminoncol.2014.09.010
Mrugala, M. M., Shi, W., Iwomoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2024). Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022. Journal of Neuro-Oncology, 169(1), 25–38. https://doi.org/10.1007/s11060-024-04682-7
Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018). Tumor-Treating Fields: a fourth modality in cancer treatment. Clinical Cancer Research, 24(2), 266–275. https://doi.org/10.1158/1078-0432.CCR-17-1117
Murphy, J., Bowers, M. E., & Barron, L. (2016). Optune(R): Practical nursing applications. Clinical Journal of Oncology Nursing, 20(5 Suppl), S14–19. https://doi.org/10.1188/16.CJON.S1.14-19
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S.,...Darlow, S. D. (2020). Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(11), 1537–1570. https://doi.org/10.6004/jnccn.2020.0052
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Brown, P.,...Engh, A. M. (2015). Central nervous system cancers, version 1.2015. Journal of the National Comprehensive Cancer Network, 13(10), 1191–1202. https://doi.org/10.6004/jnccn.2015.0148
National Comprehensive Cancer Network. (2024). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015). Immunosuppressive mechanisms in glioblastoma. Neuro-Oncology, 17 Suppl 7(Suppl 7), vii9–vii14. https://doi.org/10.1093/neuonc/nov151
Novocure GmbH. (2023). Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32). https://clinicaltrials.gov/study/NCT04471844
Novocure Inc. (2019a). FDA approves the NovoTTF-100LTM system in combination with chemotherapy for the treatment of malignant pleural mesothelioma. https://www.novocure.com/fda-approves-the-novottf-100ltm-system-in-combination-with-chemotherapy-for-the-treatment-of-malignant-pleural-mesothelioma/
Novocure Inc. (2019b). Optune (Tumor Treating Fields) [Instructions for Use]. Portsmouth, NH: Novocure Inc.
Novocure Inc. (2021). Optune Lua (Tumor Treating Fields) [Instructions for Use]. Portssmouth, NH: Novocure, Inc.
Novocure Inc. (2023a). Chat With a Buddy. https://www.optunegio.com/recently-diagnosed-gbm/buddy-calls
Novocure Inc. (2023b). Integrating Optune Gio into Practice. https://www.optunegiohcp.com/support-resources/support/optune-gio-practice-support
Novocure Inc. (2023c). MyNovocure. https://www.optunegio.com/recently-diagnosed-gbm/my-novocure
Novocure Inc. (2023d). Novocure NovoTAL System.pdf. https://www.optune.com/hcp/novotal
Novocure Inc. (2024). FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer. https://www.novocure.com/fda-approves-novocures-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-cancer/
Novocure Ltd. (2023). Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM. https://clinicaltrials.gov/study/NCT04492163#study-plan
Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2023). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro-Oncology, 25(4 suppl), iv1–iv99. https://doi.org/10.1093/neuonc/noad149
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A.,...Weller, M. (2020). Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncology, 6(7), 1003–1010. https://doi.org/10.1001/jamaoncol.2020.1024
Rivera, F., Benavides, M., Gallego, J., Guillen-Ponce, C., Lopez-Martin, J., & Kung, M. (2019). Tumor Treating Fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. Pancreatology, 19(1), 64–72. https://doi.org/10.1016/j.pan.2018.10.004
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C., Al-Tamimi, Y., & Collis, S. J. (2021). Tumour treating fields therapy for glioblastoma: Current advances and future directions. British Journal of Cancer, 124(4), 697-709. https://doi.org/10.1038/s41416-020-01136-5
Rong, L., Li, N., & Zhang, Z. (2022). Emerging therapies for glioblastoma: Current state and future directions. Journal of Experimental and Clinical Cancer Research, 41(1), 142. https://doi.org/10.1186/s13046-022-02349-7
Shi, W., Roberge, D., Kleinberg, L., Jeyapalan, S. A., Goldlust, S. A., Nagpal, S.,...Glas, M. (2023). Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma. Journal of Clinical Oncology, 41(16_suppl), TPS2083-TPS2083. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS2083
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D., Lhermitte, B.,...Ram, Z. (2017). Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA, 318(23), 2306–2316. https://doi.org/10.1001/jama.2017.18718
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V.,...Gutin, P. H. (2012). NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. European Journal of Cancer, 48(14), 2192–2202. https://doi.org/10.1016/j.ejca.2012.04.011
Taphoorn, M. J. B., Dirven, L., Kanner, A. A., Lavy-Shahaf, G., Weinberg, U., Taillibert, S.,...Stupp, R. (2018). Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: A secondary analysis of a randomized clinical trial. JAMA Oncology, 4(4), 495–504. https://doi.org/10.1001/jamaoncol.2017.5082
Toms, S. A., Kim, C. Y., Nicholas, G., & Ram, Z. (2019). Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: A subgroup analysis of the EF-14 phase III trial. Journal of Neuro-Oncology, 141(2), 467–473. https://doi.org/10.1007/s11060-018-03057-z
Vergote, I., Copeland, L., Gorp, T. V., Laenen, A., Scambia, G., Thaker, P. H.,...O’malley, D. M. (2024). #1350 Tumor treating fields (TTFields) therapy in platinum-resistant ovarian cancer: Results from the ENGOT-ov50/GOG-3029/INNOVATE-3 phase 3 study. International Journal of Gynecologic Cancer, 34(Suppl 1), A576. https://doi.org/10.1136/ijgc-2024-ESGO.1121
Vergote, I., von Moos, R., Manso, L., Van Nieuwenhuysen, E., Concin, N., & Sessa, C. (2018). Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecologic Oncology, 150(3), 471–477. https://doi.org/10.1016/j.ygyno.2018.07.018
Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S.,...Palti, Y. (2020b). Tumor-Treating Fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunology, Immunotherapy, 69(7), 1191–1204. https://doi.org/10.1007/s00262-020-02534-7
Voloshin, T., Schneiderman, R. S., Volodin, A., Shamir, R. R., Kaynan, N., Zeevi, E.,...Palti, Y. (2020a). Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics. Cancers, 12(10), 3016. https://doi.org/10.3390/cancers12103016
Zhu, J. J., Goldlust, S. A., Kleinberg, L. R., Honnorat, J., Oberheim Bush, N. A., & Ram, Z. (2022). Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: A post-approval registry study (EF-19). Discover Oncology, 13(1), 105. https://doi.org/10.1007/s12672-022-00555-5
